All In Biotech

Drug Trial Radar · NCT05353205

A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

A Double-blind , Randomized, Multicenter, Phase 4 Study to Evaluate Efficacy and Safety of Oral Flumatinib 400mg Versus 600mg in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Last checked: Nov 19, 2026Latest source record: Apr 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 23, 2021

Primary completion

Dec 30, 2022

Study completion Sep 30, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It's a double-blind , randomized ,multi-center study. The purpose of this study is to explore the efficacy and safety of flumatinib 400mg once daily (QD) versus 600mg QD as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).

Conditions

  • CML, Chronic Phase

Interventions

  • Flumatinib mesylate tablets (400mg)Drug

    Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.

  • Flumatinib mesylate tablets (600mg)Drug

    Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early molecular response(EMR) rate at 3 monthsTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Oncology, Harbin The First Hospital

    Harbin, Hei Longjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.